LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 553

Search options

  1. Book ; Online ; E-Book: Targeting oncogenic drivers and signaling pathways in lymphoid malignancies

    O'Connor, Owen A. / Ansell, Stephen M. / Seymour, John

    from concept to practice

    (Precision cancer therapies ; Volume 1)

    2023  

    Abstract: If one asks a cancer scientist a seemingly naive question such as what are the hallmarks of cancer cells, he-she will probably cite at first somatic mutations and genomic rearrangement, leading to excessive proliferation, resistance to apoptosis, and ... ...

    Author's details edited by Owen A. O'Connor, Stephen Ansell, and John Seymour
    Series title Precision cancer therapies ; Volume 1
    Abstract "If one asks a cancer scientist a seemingly naive question such as what are the hallmarks of cancer cells, he-she will probably cite at first somatic mutations and genomic rearrangement, leading to excessive proliferation, resistance to apoptosis, and dissemination potential (Hanahan and Weinberg, 2011). Intriguingly, all of these hallmarks are physiological properties of B- and T-lymphocytes, selected by evolution because they ensure an efficient immune response against pathogens. So, it is a fascinating paradox to observe that lymphoma remains a relatively rare cancer as compared to epithelial cancers. Hence, understanding the tumor suppressor mechanisms that mitigate lymphomagenesis or eradicate lymphoma cells at preclinical stages appears an extraordinary challenge. After a short overview of the current models used to analyze lymphomagenesis, we will highlight that the frontier between reactive lymphoproliferation and overt lymphoma is not always clear. Then, we will present how the classification of lymphomas based on the concept of cell of origin might reveal important phenotypical properties of lymphoma subtypes. Finally, we propose an overview of the main hallmarks of lymphomas and discuss their contribution in the most frequent subtypes of lymphomas. How to study lymphomagenesis As in other scientific fields, the nature of our knowledge of lymphomagenesis is tightly linked to the tools used to produce this knowledge. Hence, it seems interesting to start this review with a methodological perspective, providing a brief overview of the different scientific approaches which have brought major contributions to our understanding of lymphomagenesis. Epidemiology was the first approach which shed light on the mechanisms of lymphomagenesis, by deriving statistical correlations from direct observation of cohorts of patients. First, epidemiology has established the link between lymphoma incidence and aging. The incidence of most lymphomas follows an exponential growth after the fifth decade as observed for most cancers, suggesting that common processes are shared with solid tumors (Sarkozy et al., 2015; Rozhok and DeGregori, 2016). In the case of Hodgkin lymphomas, the bimodal distribution of incidence suggests that specific mechanisms are occurring in young patients, which have not been fully elucidated to date. Second, epidemiology has also proven a counter-intuitive association of lymphomas with immunosuppression, either inherited (common variable immunodepression for example) or acquired after HIV infection, or immunosuppressive drugs (van Leeuwen et al., 2009; Kaplan, 2012). This association revealed the role of the immune system in repressing the growth of transformed lymphocytes, either by active eradication of tumor cells or by exerting a competition for resources . Third, the analysis of the geographic distribution of lymphoma subtypes also shows striking differences, such as the higher incidence of T-cell lymphoma in Asia as compared to Western countries (Perry et al., 2016). These differences suggest two non-mutually exclusive hypotheses, related to environmental or genetic differences. The fourth major insight from epidemiological studies was to shed light on the role of pathogens such as Helicobacter pylori, HCV, EBV or HTLV1 in specific subtypes of lymphoma (Lecuit et al., 2004; Suarez et al., 2006; Couronné et al., 2018), which has been then confirmed experimentally. Besides pathogens, epidemiological studies have also demonstrated the role of environmental exposures such as herbicides in lymphomagenesis, which might have important consequences for health policies (Weisenburger, 2021). More recently, molecular epidemiology based on genome wide association studies have demonstrated the association of host genetic polymorphisms with the risk of specific lymphoma subtypes (Cerhan et al., 2014), highlighting unsuspected pathways which can then be experimentally explored"--
    MeSH term(s) Precision Medicine. ; Lymphoma/therapy. ; Signal Transduction.
    Keywords Cancer/Treatment
    Subject code 616.99406
    Language English
    Size 1 online resource (514 pages)
    Publisher John Wiley & Sons, Inc
    Publishing place Hoboken, New Jersey
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 1-119-81995-4 ; 1-119-81993-8 ; 9781119819929 ; 978-1-119-81995-0 ; 978-1-119-81993-6 ; 111981992X
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book ; Online: Targeting Oncogenic Drivers and Signaling Pathways in Hematologic Malignancies

    O'Conner, Owen A / Ansell, Stephen / Seymour, John F

    From Concept to Practice [Internet]

    2023  

    Keywords Medicine ; oncogenic drivers; signaling; pathways; hematologic malignancies; cancer
    Language English
    Size 1 Online-Ressource
    Publisher Wiley-Blackwell
    Document type Book ; Online
    Note English
    HBZ-ID HT030374497
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  3. Article ; Online: Risk/benefit of BTK/venetoclax combos: the context matters!

    Seymour, John F

    Blood

    2024  Volume 143, Issue 7, Page(s) 563–564

    MeSH term(s) Humans ; Waldenstrom Macroglobulinemia ; Sulfonamides ; Protein-Tyrosine Kinases ; Bridged Bicyclo Compounds, Heterocyclic ; Adenine/analogs & derivatives ; Piperidines
    Chemical Substances venetoclax (N54AIC43PW) ; ibrutinib (1X70OSD4VX) ; Sulfonamides ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Bridged Bicyclo Compounds, Heterocyclic ; Adenine (JAC85A2161) ; Piperidines
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023022896
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Approach to relapsed CLL including Richter Transformation.

    Seymour, John F

    Hematological oncology

    2023  Volume 41 Suppl 1, Page(s) 136–143

    MeSH term(s) Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Neoplasm Recurrence, Local ; Agammaglobulinaemia Tyrosine Kinase ; Cell Transformation, Neoplastic/genetics ; Protein Kinase Inhibitors
    Chemical Substances Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; Protein Kinase Inhibitors
    Language English
    Publishing date 2023-06-09
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Update on the management of relapsed/refractory chronic lymphocytic leukemia.

    Bennett, Rory / Seymour, John F

    Blood cancer journal

    2024  Volume 14, Issue 1, Page(s) 33

    Abstract: Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a relapsing and remitting pattern with sequential treatments available for many patients. Identification of progressive/relapsed CLL should prompt close monitoring ... ...

    Abstract Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a relapsing and remitting pattern with sequential treatments available for many patients. Identification of progressive/relapsed CLL should prompt close monitoring and early discussion about the next therapies when treatment indications are present. The intervening period represents an opportunity to optimize patient health, including establishing adequate vaccination and surveillance for second primary malignancies, and treating non-CLL-related comorbidities which may impact well-being and CLL therapy. We now see patients with relapsed/refractory (RR) CLL in the clinic who have been previously treated with chemoimmunotherapy (CIT) and/or one or more novel therapies. Continuous covalent inhibitors of Bruton's tyrosine kinase (cBTKi) and fixed-duration venetoclax (Ven)-anti-CD20 monoclonal antibody (mAb) are preferred over CIT given the survival advantages associated with these therapies, although have never been evaluated head-to-head. While both classes are effective for RR CLL, potential side effects and the logistics of administration differ. Few randomized data demonstrate the sequential use of cBTKi and fixed-duration Ven-anti-CD20 mAb; however, they may be used in either sequence. Newer non-covalent BTKi, active against BTK C481 resistance mutations emerging with continuous cBTKi exposure, and novel approaches such as BTK degraders, bispecific antibodies, and chimeric antigen receptor T-cell therapies demonstrate impressive efficacy. In this review of RR CLL we explore relevant investigations, consideration of broader CLL- and non-CLL-related health needs, and evidence for efficacy and safety of B-cell receptor inhibitors and Ven, including available data to support drug sequencing or switching. We describe novel approaches to RR CLL, including rechallenging with fixed-duration therapies, allogeneic stem cell transplant indications in the novel therapy era, and highlight early data supporting the use of T-cell directing therapies and novel drug targets.
    MeSH term(s) Humans ; Aged ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/etiology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Lymphoma, B-Cell/drug therapy ; Antineoplastic Agents/therapeutic use ; Agammaglobulinaemia Tyrosine Kinase ; Antibodies, Monoclonal/therapeutic use
    Chemical Substances Antineoplastic Agents ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; Antibodies, Monoclonal
    Language English
    Publishing date 2024-02-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-024-01001-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.

    Seymour, John F

    Blood advances

    2022  Volume 6, Issue 4, Page(s) 1365–1370

    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Protein Kinase Inhibitors
    Chemical Substances Protein Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2022-01-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2019001205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: CLL12: a positive answer to a poorly phrased question.

    Seymour, John F

    Blood

    2022  Volume 139, Issue 2, Page(s) 151–152

    Language English
    Publishing date 2022-01-13
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2021014616
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.

    Seymour, John F

    Leukemia & lymphoma

    2021  Volume 62, Issue 10, Page(s) 2299–2302

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Rituximab/therapeutic use
    Chemical Substances Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2021-09-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1984462
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Marginal zone lymphoma: 2023 update on diagnosis and management.

    Cheah, Chan Y / Seymour, John F

    American journal of hematology

    2023  Volume 98, Issue 10, Page(s) 1645–1657

    Abstract: Disease overview: Marginal zone lymphomas (MZL) are collectively the second most common type of indolent lymphoma.: Diagnosis: Three subtypes of MZL are recognized: splenic, extranodal, and nodal. The diagnosis is secured following biopsy of an ... ...

    Abstract Disease overview: Marginal zone lymphomas (MZL) are collectively the second most common type of indolent lymphoma.
    Diagnosis: Three subtypes of MZL are recognized: splenic, extranodal, and nodal. The diagnosis is secured following biopsy of an involved nodal or extranodal site demonstrating a clonal B-cell infiltrate with CD5 and CD10 negative immunophenotype most common. Some cases will features IgM paraprotein, but MYD88 L256P mutations are less frequent than in Waldenstrom macroglobulinemia. Prognostication Several prognostic models have been developed, including the MALT-IPI and the MZL-IPI. The latter is broadly applicable across MZL subtypes and incorporates elevated serum LDH, anemia, lymphopenia, thrombocytopenia and nodal or disseminated subtypes as independent predictors of outcome.
    Treatment: We discuss suggested approach to therapy for both early and advanced-stage disease, with reference to chemo-immunotherapy, radiotherapy, and emerging treatments in relapsed/refractory disease such as BTK inhibitors.
    MeSH term(s) Humans ; Lymphoma, B-Cell, Marginal Zone/diagnosis ; Lymphoma, B-Cell, Marginal Zone/genetics ; Lymphoma, B-Cell, Marginal Zone/therapy ; B-Lymphocytes ; Adaptor Proteins, Signal Transducing ; Biopsy ; Immunophenotyping
    Chemical Substances Adaptor Proteins, Signal Transducing
    Language English
    Publishing date 2023-08-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Choosing between family members is always a balancing act.

    Bennett, Rory / Seymour, John F

    Haematologica

    2023  Volume 108, Issue 8, Page(s) 1975–1978

    Language English
    Publishing date 2023-08-01
    Publishing country Italy
    Document type Editorial ; Comment
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.282628
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top